Disappointing Chinese Vaccine Results Pose Setback for Developing World

[CAPRICORN-88]

 

[Beast]

go drink something from your CMPT bot coolaid. No one is listening to your PLA troll bot factory kak.

My ignore list of CMPT insect is getting larger and larger.

@waz @The Eagle. Name calling and useless reply with no meaning in this thread.

Please take care , issue warning to poster and clean the thread. Thank you

 

[CAPRICORN-88]

chinese here call new strain British virus but others are racist and not chinese.... everyone is now aware of how chinese vaccine failed... and Brazil showed the world that sinovac efficacy is at 50.4% which is really really bad.

I will be interested to know who are the everyone? I for one didn't know that.

The world should be grateful to China as this virus was ravaging in the West and USA diagnosed as a common flu until China CDC identified it.

Now Chinese scientists discovered a new strain of virus in Wuhan and it is then called Wuhan and Trump later politicized it and called it China Virus in his campaign. That is called US Psyops.

But Pelosi also called US virus Trump Virus.
Then I don't see what is wrong in calling this strain UK virus based on this line of reasoning since the new strain is indeed discovered in UK.

Stop being double standard.
So the British don't like it and expects the Chinese to swallow it.

 

[CAPRICORN-88]

https://www.globaltimes.cn/page/202101/1212948.shtml

Brazil's health regulator Anvisa on Thursday urged AstraZeneca and Sinovac-Butantan to submit further documentation required for their COVID-19 vaccines' getting emergency use approval on Sunday.

A source close to Sinovac told the Global Times on Friday that the company and its Brazilian partner Butantan have supplemented the documentation as requested.

Turkish President Tayyip Erdogan received the first dose of Sinovac's COVID-19 vaccine CoronaVac on Thursday, becoming the second country's president to use the CoronaVac after Indonesian President Joko Widodo.

Despite their vaccination reflects a trust in the shots and boosts higher confidence in CoronaVac, some Western media took aim at Chinese vaccines' efficacy while, as medical experts criticized, unscientifically putting CoronaVac in comparison with Pfizer and Moderna's mRNA vaccines, which reported over 90 percent protection rate.

Vaccine's efficacy varies so much in the design of clinical trials, in the selection of volunteers, and in the number of infected people, that comparisons cannot be made without discrimination, experts warned.

Shao Yiming from China's Centers for Disease Control and Prevention (CDC), who was involved in China's COVID-19 vaccine approval, told the Global Times on Friday that the Chinese drug authorities obtained the final-stage data as early as the end of October 2020, but maintained a very careful and detailed review procedure before conditional approval, partly due to data complexity.

According to the WHO Clinical Progression Scale, the scale provides a measure of illness severity across a range from class 0 (not infected) to class 10 (dead) with data elements that are rapidly obtainable from clinical records.

Sinovac's vaccine had a 50.4 percent efficacy if calculated with infected numbers in the trials at class 2 (symptomatic, but no assistance needed) and above.

But when researchers calculated the infected ones with class 3 (symptomatic, assistance needed) and above criteria, its efficacy can reach as high as 78 percent.

However, scientists generally believe that it is difficult to make a clear distinction between class 2 and class 3, and the description and definition of all symptoms depend mainly on volunteers' subjective judgment and description, which also brings great differences in conclusions.

Among almost all vaccines' trials globally, only two mRNA vaccines in the US have contrasted with the general clinical rule that the placebo group in the clinical study has a significantly higher incidence rate than the local natural rate, due to the researchers' close monitoring. This has led to suspicions that American researchers are applying a more rigorous standard in defining symptoms of volunteers in order to get better data on effectiveness, according to Shao.

However, researchers in CoronaVac's trials "chose the broadest number of symptoms, and like to capture even the simplest symptoms," Ricardo Palacios, the medical director of Butantan, said at the press meeting on Tuesday. "Those symptoms have not been included on similar studies. Our study was the one with the lowest class among all of the studies conducted."

Health care workers in the Brazilian trial were more sensitive to symptoms and more likely to amplify them than ordinary volunteers with other vaccines, according to analysts.

In addition, the environmental risks involved in different trials can also affect the effectiveness of the vaccine.

Palacios stressed on Tuesday that the trials in Brazil selected "the most challenging conditions for the vaccine," and he used a metaphor like "comparing runners on a flat surface versus a runner on an elevated terrain with obstacles." The challenges of this vaccine were the population involved - medical workers that are at risk of high exposure - which would decrease the vaccine's protection efficacy.

"We deliberated the choice of the most challenging conditions. Those tests would prove that the vaccine would work well under normal conditions," Palacios said.

Except for Coronavac, the other vaccines, including those developed by Pfizer, Moderna and AstraZeneca, were all tested on the general population, most of which require people aged 18 and older.

While Pfizer and Moderna's Phase III trials are almost mainly conducted and analyzed by the drug giants themselves, CoronaVac's trial in Brazil was conducted by the Butantan Institute and the results were analyzed and supervised by a third party, Shao noted. The whole process and results review are relatively independent from the producer.

"China is one of the first countries to receive Phase III clinical data in October. But unlike the US, vaccine manufacturers are not allowed to publish data without approval.

China's drug administration aims to conduct a scientific and accountable assessment of the data in a condition free of public opinion pressure," Shao said.

 

[Hamartia Antidote]

If measured by the same standard, what is the effectiveness of Western vaccines such as Pfizer?
Why did Pfizer executives sell stocks?

He had filed a 10b5-1 in August saying he would sell on Nov 10th

Rule 10b5-1 Definition, How It Works, SEC Requirements

The SEC's Rule 10b5-1 allows stock trades to be set up in advance by public companies' officers or directors to avoid accusations of insider trading.

www.investopedia.com

 

[Chhatrapati]

Brazil showed the world that sinovac efficacy is at 50.4% which is really really bad.

It's just above the acceptable limit. Nobody knows the long term efficacy of the vaccine and unless until the whole world is vaccinated this Coronavirus is not over.

 

[Ali_Baba]

The solution for the pandemic is the AstraZeneca/Oxford vaccine, it has the required success level, ease of transport and also safety.

 

[xuxu1457]

chinese here call new strain British virus but others are racist and not chinese.... everyone is now aware of how chinese vaccine failed... and Brazil showed the world that sinovac efficacy is at 50.4% which is really really bad.

In fact, according to WHO standards, the vaccine is 50% effective qualified can be listed，More than 90% effective in the vaccine is actually abnormalBecause of the potential for serious side effects of increasing the dose，All the effects are related to dose, and dose is related to side effects.

 

[Desi_Guy]

Disappointing Chinese Vaccine Results Pose Setback for Developing World (Published 2021)

Brazil says CoronaVac has an efficacy rate just over 50 percent, much lower than previously announced. More than 380 million doses have already been ordered.

www.nytimes.com

Brazil says CoronaVac has an efficacy rate just over 50 percent, much lower than previously announced. More than 380 million doses have already been ordered.


Scientists in Brazil have downgraded the efficacy of a Chinese coronavirus vaccine that they hailed as a major triumph last week, diminishing hopes for a shot that could be quickly produced and easily distributed to help the developing world.

Officials at the Butantan Institute in São Paulo said on Tuesday that a trial conducted in Brazil showed that the CoronaVac vaccine, manufactured by the Beijing-based company Sinovac, had an efficacy rate just over 50 percent. That rate, slightly above the benchmark that the World Health Organization has said would make a vaccine effective for general use, was far below the 78 percent level announced last week.

The implications could be significant for a vaccine that is crucial to China’s global health diplomacy. At least 10 countries have ordered more than 380 million doses of the Sinovac inoculation, CoronaVac, though regulatory agencies have yet to fully approve it.

A senior official in Hong Kong, a special administrative region of China that had already ordered CoronaVac, said on Wednesday that an advisory panel would strictly review the vaccine based on clinical trial data before it was rolled out there.

“Those countries that have ordered the Chinese-made vaccines are probably going to question the usefulness of these vaccines,” said Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations and an expert on health care in China.

“Countries with opposition parties might use this to challenge the decision made by the incumbent government, and that will likely have domestic political implications in these countries,” Mr. Huang said.

Sinovac did not respond to multiple requests for comment.

For months, Chinese officials had said that the vaccines made by Sinovac and Sinopharm, a state-owned vaccine maker, would be important tools for fighting the pandemic in poorer countries that do not have extensive health care infrastructures. Unlike the vaccines made by the American drugmakers Pfizer and Moderna, they do not need to be frozen.

The Oxford-AstraZeneca and Johnson & Johnson vaccines, which can be refrigerated and are more effective than their Chinese counterparts, could provide an alternative. But it is now unclear if the governments that have bought CoronaVac can scrap their deals and turn to others.

CoronaVac, unlike some of the other vaccines, relies on older technology that uses chemicals to weaken or kill the virus, which is then put into a vaccine to spark antibodies in the recipient. But the process of killing the virus can weaken a vaccine’s potency, resulting in an immune response that could be shorter or less effective.

The lower efficacy announced Tuesday would mean it would take longer for countries that use CoronaVac’s vaccine to reach “herd immunity,” the point at which enough people are resistant to the virus — roughly 70 percent, many scientists have said — that it is vanquished in a population. By contrast, the vaccines made by Moderna and Pfizer-BioNTech have been shown to have an efficacy rate of about 95 percent.

“This was one of the reasons the Americans and Europeans didn’t go with this older technology,” said John Moore, a vaccine expert at Cornell University. “A well-maintained Ford Model T would probably get you from Wuhan to Beijing, but personally I would prefer a Tesla.”

Brazil’s health regulatory agency, Anvisa, is reviewing data from the trial, which relied on volunteers who are health care professionals. If Anvisa approves emergency use of CoronaVac, officials hope to start giving out shots in Brazil late this month. It has roughly 10.8 million doses of CoronaVac on hand. Last week, Brazil’s health minister, Eduardo Pazuello, said the government intended to purchase 100 million doses of CoronaVac.

Natalia Pasternak, a microbiologist and the president of Instituto Questão de Ciência, a Brazilian nongovernmental organization, told reporters on Tuesday that the results of the trial meant it would not be a panacea.

“It is not the best vaccine in the world,” she said at the news conference during which the efficacy rate was disclosed. But she called it a “perfectly acceptable vaccine” that would lead to fewer patients developing serious cases or dying from the virus.

Made in China will always remain cheap.

The solution for the pandemic is the AstraZeneca/Oxford vaccine, it has the required success level, ease of transport and also safety.

So Pakistanis will now be at the mercy of Indian manufacturing company ??
O’ the self respect.

 

[denel]

The solution for the pandemic is the AstraZeneca/Oxford vaccine, it has the required success level, ease of transport and also safety.

This remains the best and viable, I took part in these trails back in Sept here.

https://www.globaltimes.cn/page/202101/1212948.shtml

Brazil's health regulator Anvisa on Thursday urged AstraZeneca and Sinovac-Butantan to submit further documentation required for their COVID-19 vaccines' getting emergency use approval on Sunday.

A source close to Sinovac told the Global Times on Friday that the company and its Brazilian partner Butantan have supplemented the documentation as requested.

Turkish President Tayyip Erdogan received the first dose of Sinovac's COVID-19 vaccine CoronaVac on Thursday, becoming the second country's president to use the CoronaVac after Indonesian President Joko Widodo.

Despite their vaccination reflects a trust in the shots and boosts higher confidence in CoronaVac, some Western media took aim at Chinese vaccines' efficacy while, as medical experts criticized, unscientifically putting CoronaVac in comparison with Pfizer and Moderna's mRNA vaccines, which reported over 90 percent protection rate.

Vaccine's efficacy varies so much in the design of clinical trials, in the selection of volunteers, and in the number of infected people, that comparisons cannot be made without discrimination, experts warned.

Shao Yiming from China's Centers for Disease Control and Prevention (CDC), who was involved in China's COVID-19 vaccine approval, told the Global Times on Friday that the Chinese drug authorities obtained the final-stage data as early as the end of October 2020, but maintained a very careful and detailed review procedure before conditional approval, partly due to data complexity.

According to the WHO Clinical Progression Scale, the scale provides a measure of illness severity across a range from class 0 (not infected) to class 10 (dead) with data elements that are rapidly obtainable from clinical records.

Sinovac's vaccine had a 50.4 percent efficacy if calculated with infected numbers in the trials at class 2 (symptomatic, but no assistance needed) and above.

But when researchers calculated the infected ones with class 3 (symptomatic, assistance needed) and above criteria, its efficacy can reach as high as 78 percent.

However, scientists generally believe that it is difficult to make a clear distinction between class 2 and class 3, and the description and definition of all symptoms depend mainly on volunteers' subjective judgment and description, which also brings great differences in conclusions.

Among almost all vaccines' trials globally, only two mRNA vaccines in the US have contrasted with the general clinical rule that the placebo group in the clinical study has a significantly higher incidence rate than the local natural rate, due to the researchers' close monitoring. This has led to suspicions that American researchers are applying a more rigorous standard in defining symptoms of volunteers in order to get better data on effectiveness, according to Shao.

However, researchers in CoronaVac's trials "chose the broadest number of symptoms, and like to capture even the simplest symptoms," Ricardo Palacios, the medical director of Butantan, said at the press meeting on Tuesday. "Those symptoms have not been included on similar studies. Our study was the one with the lowest class among all of the studies conducted."

Health care workers in the Brazilian trial were more sensitive to symptoms and more likely to amplify them than ordinary volunteers with other vaccines, according to analysts.

In addition, the environmental risks involved in different trials can also affect the effectiveness of the vaccine.

Palacios stressed on Tuesday that the trials in Brazil selected "the most challenging conditions for the vaccine," and he used a metaphor like "comparing runners on a flat surface versus a runner on an elevated terrain with obstacles." The challenges of this vaccine were the population involved - medical workers that are at risk of high exposure - which would decrease the vaccine's protection efficacy.

"We deliberated the choice of the most challenging conditions. Those tests would prove that the vaccine would work well under normal conditions," Palacios said.

Except for Coronavac, the other vaccines, including those developed by Pfizer, Moderna and AstraZeneca, were all tested on the general population, most of which require people aged 18 and older.

While Pfizer and Moderna's Phase III trials are almost mainly conducted and analyzed by the drug giants themselves, CoronaVac's trial in Brazil was conducted by the Butantan Institute and the results were analyzed and supervised by a third party, Shao noted. The whole process and results review are relatively independent from the producer.

"China is one of the first countries to receive Phase III clinical data in October. But unlike the US, vaccine manufacturers are not allowed to publish data without approval.

China's drug administration aims to conduct a scientific and accountable assessment of the data in a condition free of public opinion pressure," Shao said.

Classic false reporting. You do NOT give vaccine to already infected people. That is not how it is done.

https://www.globaltimes.cn/page/202101/1212948.shtml

Brazil's health regulator Anvisa on Thursday urged AstraZeneca and Sinovac-Butantan to submit further documentation required for their COVID-19 vaccines' getting emergency use approval on Sunday.

A source close to Sinovac told the Global Times on Friday that the company and its Brazilian partner Butantan have supplemented the documentation as requested.

Turkish President Tayyip Erdogan received the first dose of Sinovac's COVID-19 vaccine CoronaVac on Thursday, becoming the second country's president to use the CoronaVac after Indonesian President Joko Widodo.

Despite their vaccination reflects a trust in the shots and boosts higher confidence in CoronaVac, some Western media took aim at Chinese vaccines' efficacy while, as medical experts criticized, unscientifically putting CoronaVac in comparison with Pfizer and Moderna's mRNA vaccines, which reported over 90 percent protection rate.

Vaccine's efficacy varies so much in the design of clinical trials, in the selection of volunteers, and in the number of infected people, that comparisons cannot be made without discrimination, experts warned.

Shao Yiming from China's Centers for Disease Control and Prevention (CDC), who was involved in China's COVID-19 vaccine approval, told the Global Times on Friday that the Chinese drug authorities obtained the final-stage data as early as the end of October 2020, but maintained a very careful and detailed review procedure before conditional approval, partly due to data complexity.

According to the WHO Clinical Progression Scale, the scale provides a measure of illness severity across a range from class 0 (not infected) to class 10 (dead) with data elements that are rapidly obtainable from clinical records.

Sinovac's vaccine had a 50.4 percent efficacy if calculated with infected numbers in the trials at class 2 (symptomatic, but no assistance needed) and above.

But when researchers calculated the infected ones with class 3 (symptomatic, assistance needed) and above criteria, its efficacy can reach as high as 78 percent.

However, scientists generally believe that it is difficult to make a clear distinction between class 2 and class 3, and the description and definition of all symptoms depend mainly on volunteers' subjective judgment and description, which also brings great differences in conclusions.

Among almost all vaccines' trials globally, only two mRNA vaccines in the US have contrasted with the general clinical rule that the placebo group in the clinical study has a significantly higher incidence rate than the local natural rate, due to the researchers' close monitoring. This has led to suspicions that American researchers are applying a more rigorous standard in defining symptoms of volunteers in order to get better data on effectiveness, according to Shao.

However, researchers in CoronaVac's trials "chose the broadest number of symptoms, and like to capture even the simplest symptoms," Ricardo Palacios, the medical director of Butantan, said at the press meeting on Tuesday. "Those symptoms have not been included on similar studies. Our study was the one with the lowest class among all of the studies conducted."

Health care workers in the Brazilian trial were more sensitive to symptoms and more likely to amplify them than ordinary volunteers with other vaccines, according to analysts.

In addition, the environmental risks involved in different trials can also affect the effectiveness of the vaccine.

Palacios stressed on Tuesday that the trials in Brazil selected "the most challenging conditions for the vaccine," and he used a metaphor like "comparing runners on a flat surface versus a runner on an elevated terrain with obstacles." The challenges of this vaccine were the population involved - medical workers that are at risk of high exposure - which would decrease the vaccine's protection efficacy.

"We deliberated the choice of the most challenging conditions. Those tests would prove that the vaccine would work well under normal conditions," Palacios said.

Except for Coronavac, the other vaccines, including those developed by Pfizer, Moderna and AstraZeneca, were all tested on the general population, most of which require people aged 18 and older.

While Pfizer and Moderna's Phase III trials are almost mainly conducted and analyzed by the drug giants themselves, CoronaVac's trial in Brazil was conducted by the Butantan Institute and the results were analyzed and supervised by a third party, Shao noted. The whole process and results review are relatively independent from the producer.

"China is one of the first countries to receive Phase III clinical data in October. But unlike the US, vaccine manufacturers are not allowed to publish data without approval.

China's drug administration aims to conduct a scientific and accountable assessment of the data in a condition free of public opinion pressure," Shao said.

Classic false reporting. You do NOT give vaccine to already infected people. That is not how it is done.

Made in China will always remain cheap.

So Pakistanis will now be at the mercy of Indian manufacturing company ??
O’ the self respect.

There is nothing wrong with Indian Pharma - they supply most of the medication worldwide. Credit is due where it needs to be.
In terms of China vacc--- people forget this is the same country where children milk is contaminated and chinese population will not buy local brands due to melamine lacing.

 

[denel]

https://www.bloomberg.com/news/arti...f-vaccination-risks-for-sick-patients-over-80

Simple - Most over 80s have poor immunity systems and any vaccine can be challenging.

 

[CAPRICORN-88]

This remains the best and viable, I took part in these trails back in Sept here.

Classic false reporting. You do NOT give vaccine to already infected people. That is not how it is done.

Classic false reporting. You do NOT give vaccine to already infected people. That is not how it is done.

There is nothing wrong with Indian Pharma - they supply most of the medication worldwide. Credit is due where it needs to be.
In terms of China vacc--- people forget this is the same country where children milk is contaminated and chinese population will not buy local brands due to melamine lacing.

So you are challenging the experts calling them fake.
You must be a virologist yourself then or a fake news reporter from WION.

So who is fake?
Go home and stop trolling while hundreds of millions of Indians are praying daily for a vaccine jabs. They will probably get one and will have to pray even harder for a second shot if they are lucky.

 

[Beast]

So you are challenging the experts calling them fake.
You must be a virologist yourself then or a reporter with WION.

Most of his post are joke and I am highly doubt he is south african.

 

[khansaheeb]

Pfizer vaccines unsafe too:-

Covid vaccine horror as 23 people suddenly die after taking jab

NORWAY has reported 23 elderly people have died just days after taking the COVID-19 vaccine.

www.express.co.uk

 

[denel]

So you are challenging the experts calling them fake.
You must be a virologist yourself then or a reporter with WION.

Well I am a scientist; so yes there are protocols to every trials.... it seems you people in your propaganda ministry fail to check your numbers and verbiage correct. No disrespect to my real chinese researchers who do their work diligently;
No time for riffraf propaganda bs. another bat pla troll to add to my ignore list.
Moderators must do a complete purge of all the PLA troll flies all over this forum.